• ATRIVA Therapeutics

    First-in-class host-targeting antiviral therapies against severe respiratory viral infections, including influenza and potentially coronaviruses.


    Great potential against influenza virus due to antiviral and immunomodulating activity of ATRIVA’s lead product ATR-002.

    Phase I clinical trial successfully completed, Phase II in influenza under preparation.


    Learn more


  • ATRIVA Therapeutics

    Invest in research to contribute to pandemic preparedness!


    We invite you to explore our approach and development milestones presented on this website and encourage you to contact us directly.


    Get in touch


  • 1
  • 2
  • First-in-class host-targeting antiviral therapies against severe respiratory viral infections, including influenza and potentially coronaviruses.

    Learn more
  • Invest in research to contribute to pandemic preparedness!

    Get in touch
  • 1
  • 2

About Us

Learn more about the team behind ATRIVA Therapeutics GmbH.

 

Read more

The ATRIVA Approach

Novel host-targeting approach to prevent viral replication.

 

Read more

  • News
  • Atriva Therapeutics to present at the BIO-Europe in Hamburg

Atriva Therapeutics to take part in three major conferences in San Francisco, USA, in the upcoming week

Continue Reading

Atriva Therapeutics takes part in four conferences in the upcoming months

 Tübingen (Germany), September 4, 2019 – Atriva Therapeutics GmbH, a biopharma­ceutical company pioneering the development of host-targeting antiviral therapies, today announced its participation in four upcoming partnering conferences worldwide.

Continue Reading

 

Atriva Therapeutics is one of four companies to receive the Biomarker Validation Award and aims to validate a biomarker for monitoring of MEK inhibition by the clinical-stage influenza therapy ATR-002. The award will be in the form of lab services with the Integrated Biobank of Luxembourg.

Continue Reading

Latest News

Contact Form

Please, enter your name
Please, enter your phone number
Please, enter your e-mail address Mail address is not not valid
Please, enter your message

Address

Atriva Therapeutics GmbH
Christophstr. 32, 72072 Tübingen

+49 (0)7071 8597673
info@atriva-therapeutics.com

LinkedIn
Twitter

In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.